BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/20
Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered MondayThe Motley Fool • 03/16/20
Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority ReviewThe Motley Fool • 02/21/20
5 Goldman Sachs Conviction List Stocks With Massive Upside Potential for 202024/7 Wall Street • 01/10/20